Cyclerion CFO exercises 25,000 stock options

Cyclerion Therapeutics, Inc. (CYCN) reported that its Chief Financial Officer, Rhonda M. Chicko, exercised stock options for 25,000 shares of common stock on August 14, 2026 at an exercise price of $2.355 per share, paid in cash.

Rhea-AI Filing Summary

Cyclerion Therapeutics, Inc. (CYCN) reported that its Chief Financial Officer, Rhonda M. Chicko, exercised stock options for 25,000 shares of common stock on August 14, 2026 at an exercise price of $2.355 per share, paid in cash. These options, granted on August 7, 2025 under the 2019 Equity Incentive Plan and originally vesting over time, had all remaining vesting accelerated by the board on July 17, 2026. After the exercise, Chicko directly holds 25,018 shares of common stock and no remaining options from this specific grant.

Insider Trade Summary

25,000 shares exercised/converted

Exercise 2 txns

Insider CHICKO RHONDA M.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Option to Purchase F1	25,000	$0.00	$0.00
Exercise	Common Stock, no par value F1	25,000	$2.355	$59K

Holdings After Transaction: Option to Purchase — 0 contracts (Direct); Common Stock, no par value — 25,018 shares (Direct)

Footnotes (1)

1. F1. The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price.

Key Figures

Options Exercised: 25,000 shares Exercise Price: $2.355 per share Post-Transaction Holdings: 25,018 shares +3 more

6 metrics

Options Exercised 25,000 shares Shares of common stock underlying options exercised on August 14, 2026

Exercise Price $2.355 per share Exercise price of the option grant covering 25,000 shares

Post-Transaction Holdings 25,018 shares Total common stock directly held by the CFO after the transaction

Option Grant Size 25,000 shares Maximum number of shares under the option granted August 7, 2025

Option Expiration Date 2035-08-06 Expiration date of the option that was exercised in full

Accelerated Vesting Date July 17, 2026 Date the board accelerated vesting of all then-unvested options

Key Terms

2019 Equity Incentive Plan, vest ratably, exercise price, expiration date

4 terms

2019 Equity Incentive Plan financial

"to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan"

vest ratably financial

"the remaining 16,250 shares were to vest ratably in monthly installments"

exercise price financial

"conversion_or_exercise_price": "2.3550""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2035-08-06""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYCN’s CFO report on this Form 4?

Cyclerion’s CFO Rhonda M. Chicko exercised options for 25,000 shares of common stock on August 14, 2026 at an exercise price of $2.355 per share, paying cash to the company and converting the options into directly held common stock.

How many CYCN shares does the CFO own after the August 14, 2026 transaction?

After the option exercise, CFO Rhonda M. Chicko directly holds 25,018 shares of Cyclerion common stock. The exercised grant covered 25,000 shares, and the Form 4 reports 25,018 shares as the total direct common stock ownership following the transaction.

What was the exercise price for the CYCN stock options used by the CFO?

The exercised Cyclerion stock options had an exercise price of $2.355 per share. On August 14, 2026, the CFO exercised all 25,000 option shares and paid the full purchase price in cash directly to Cyclerion Therapeutics, Inc.

When were the CYCN options originally granted and under what plan?

The options were granted on August 7, 2025 to purchase up to 25,000 shares of Cyclerion common stock under the company’s 2019 Equity Incentive Plan. They included immediate and monthly vesting components before later being fully accelerated.

Did CYCN’s board take any action affecting the CFO’s option vesting?

Yes. On July 17, 2026, Cyclerion’s Board of Directors accelerated in full the vesting of all then unvested options held by the CFO under this grant, allowing her to exercise the entire 25,000-share option position on August 14, 2026.

How were the CYCN option shares paid for in the CFO’s exercise?

The CFO paid cash to Cyclerion for the exercise of all 25,000 option shares. According to the disclosure, she exercised the option in full on August 14, 2026 and paid the full purchase price in cash, rather than using share withholding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 05:27 PM EDT Accepted by SEC EDGAR 08/18/2026 - 05:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHICKO RHONDA M.

(Last) (First) (Middle)

C/O CYCLERION THERAPEUTICS, INC.

245 FIRST STREET, 18TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cyclerion Therapeutics, Inc. [ CYCN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, no par value	08/14/2026		M(1)		25,000	A	$2.355	25,018	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase	$2.355	08/14/2026		M(1)			25,000	(1)	08/06/2035	Common Stock	25,000	$0	0	D

Explanation of Responses:

1. The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price.

	/s/ Rhonda Chicko	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)